Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combinat...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2009-10, Vol.29 (10), p.4083
Main Authors: Yen, Yun, So, Samuel, Rose, Michal, Saif, M Wasif, Chu, Edward, Liu, Shwu-Huey, Foo, Angeline, Jiang, Zaoli, Su, Tahmun, Cheng, Yung-Chi
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Capecitabine
Carcinoma, Hepatocellular - drug therapy
Deoxycytidine - administration & dosage
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Dose-Response Relationship, Drug
Drugs, Chinese Herbal - administration & dosage
Drugs, Chinese Herbal - adverse effects
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Fluorouracil - analogs & derivatives
Humans
Liver Neoplasms - drug therapy
Male
Middle Aged
Quality of Life
Survival Rate
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (16.5 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.
ISSN:0250-7005
1791-7530